Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6 ...
Shares of Vera Therapeutics (VERA) sold off about 20% on Friday following news in competitor Otsuka’s 2024 earnings presentation that the ...
Evercore ISI analyst Stephen Richardson maintained a Buy rating on Conocophillips (COP – Research Report) on February 14 and set a price target ...
Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...
Evercore ISI made an adjustment to its price target for Lyft stock (NASDAQ:LYFT), reducing it to $15.00 from the previous $19 ...
Specialty MGA Optio Group has retained investment bank Evercore with a mandate to explore its debt options, as the business ...
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” ...
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning run and other plays he's watching in the market.
Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...
James Yaro; Analyst; Goldman Sachs & Company, Inc. Brendan O’Brien; Analyst; Wolfe Research Aidan Hall; Analyst; Keefe, Bruyette & Woods, Inc. Good morning and welcome to the Evercore fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results